This is an NIH/NCI grant for organizations that already have an analytically validated cancer biomarker assay and need to validate it clinically using specimens from existing trials or studies. It is not for early-stage technology development or clinical trials. Small businesses and for-profits can apply, but if you have no established assay or no access to clinical specimens, do not bother.
| Industry | Estimated fit |
|---|---|
| Healthcare & BiotechMatches your industry (clinical) | 69 |
| Technology & SoftwareMatches your industry (technology, tech) | 61 |
| Environment & ConservationLimit: Closes in 26 days | 54 |
| Energy & Clean TechLimit: Closes in 26 days | 53 |
| Social Services & NonprofitLimit: Closes in 26 days | 53 |
| Arts & CultureLimit: Closes in 26 days | 52 |
| Industry | Estimated fit |
|---|---|
| Education & TrainingLimit: Closes in 26 days | 51 |
| Food & BeverageLimit: Closes in 26 days | 49 |
| Housing & Real EstateLimit: Closes in 26 days | 49 |
| ManufacturingLimit: Closes in 26 days | 48 |
| Agriculture & FarmingLimit: Closes in 26 days | 47 |
| Finance & BankingLimit: Closes in 26 days | 45 |
| Retail & E-CommerceLimit: Closes in 26 days | 44 |
| Transportation & LogisticsLimit: Closes in 26 days | 43 |
| Construction & InfrastructureLimit: Closes in 26 days | 42 |
These are our matcher’s estimates for a typical business in each industry. A real match depends on your size, your state and what you need the money for — check your own fit.
NIH/NCI UH3 cooperative agreement to clinically validate established molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, or treatment response using specimens from clinical trials or studies. Eligible applicants include small businesses, for-profit organizations, nonprofits, universities, state/local/tribal governments, and federal agencies; U.S
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Topics
Open opportunities funding similar work, from the same funder or in the same place.
NIH BRAIN Initiative grants to develop tools and computational models for high-resolution, synchronous measurement of complex behaviors alongside neural activity in humans and other species. Eligible applicants include…
NIH/NCI K99/R00 career-development award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent tenure-track faculty positions; requires the candidate to lead an…
NIH/NCI K99/R00 award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent faculty careers. The applicant is typically the sponsoring institution; eligible…
NIH/NCI cooperative agreement (UH2/UH3) funding validation of molecular, cellular, and imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response. Open to universities,…
NIH/NCI program funding revision applications to adapt and clinically validate molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response prediction.…
NIH/NCCIH forecasted R33 grant for multisite feasibility studies of mind and body interventions (meditation, yoga, acupuncture, music) on whole person health restoration. Eligible: small businesses, for-profits,…